SXTC
China SXT Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$671K
5Y Perf.-100.0%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
SXTC vs SBFM vs CRVS vs IMVT vs CRL
Revenue, margins, valuation, and 5-year total return — side by side.
SBFM
Sunshine Biopharma, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$758K
5Y Perf.-99.4%
CRVS
Corvus Pharmaceuticals, Inc.
Biotechnology
Market Cap$1.23B
5Y Perf.+322.9%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.+6.1%
CRL
Charles River Laboratories International, Inc.
Medical - Diagnostics & Research
Market Cap$8.98B
5Y Perf.+1.3%
SXTC vs SBFM vs CRVS vs IMVT vs CRL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SXTC | SBFM | CRVS | IMVT | CRL |
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Biotechnology | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $671K | $758K | $1.23B | $5.53B | $8.98B |
| Revenue (TTM) | $2M | $36M | $0.00 | $0.00 | $4.03B |
| Net Income (TTM) | $-3M | $-6M | $-44M | $-464M | $-185M |
| Gross Margin | 21.1% | 33.3% | — | — | 24.9% |
| Operating Margin | -154.0% | -17.9% | — | — | 11.8% |
| Forward P/E | — | — | — | — | 16.4x |
| Total Debt | $984K | $952K | $937K | $98K | $3.07B |
| Cash & Equiv. | $18M | $10M | $5M | $714M | $214M |
SXTC vs SBFM vs CRVS vs IMVT vs CRL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SXTC
SBFM
CRVS
IMVT
CRL
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| China SXT Pharmaceu… (SXTC) | 100 | 0.0 | -100.0% |
| Sunshine Biopharma,… (SBFM) | 100 | 0.6 | -99.4% |
| Corvus Pharmaceutic… (CRVS) | 100 | 422.9 | +322.9% |
| Immunovant, Inc. (IMVT) | 100 | 106.1 | +6.1% |
| Charles River Labor… (CRL) | 100 | 101.3 | +1.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SXTC vs SBFM vs CRVS vs IMVT vs CRL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CRVS leads in 2 of 6 categories (5-stock set), making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. China SXT Pharmaceuticals, Inc. is the stronger pick specifically for capital preservation and lower volatility. SBFM and CRL also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
SXTC
China SXT Pharmaceuticals, Inc.
The Income Pick
SXTC is the #2 pick in this set and the best alternative if income & stability is your priority.
- beta 1.16
- Beta 1.16 vs CRVS's 1.63
Best for: income & stability
SBFM
Sunshine Biopharma, Inc.
The Growth Play
SBFM ranks third and is worth considering specifically for growth exposure.
- Rev growth 44.7%, EPS growth 97.9%, 3Y rev CAGR 434.5%
- 44.7% revenue growth vs IMVT's -21.3%
Best for: growth exposure
CRVS
Corvus Pharmaceuticals, Inc.
The Quality Compounder
CRVS carries the broadest edge in this set and is the clearest fit for quality and momentum.
- 3.5% margin vs SXTC's -189.8%
- +355.9% vs SXTC's -99.4%
Best for: quality and momentum
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- 173.6% 10Y total return vs CRVS's 17.1%
- Lower volatility, beta 1.37, Low D/E 0.0%, current ratio 11.16x
- Beta 1.37, current ratio 11.16x
Best for: long-term compounding and sleep-well-at-night
CRL
Charles River Laboratories International, Inc.
The Niche Pick
CRL is the clearest fit if your priority is efficiency.
- -2.5% ROA vs IMVT's -44.1%
Best for: efficiency
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SBFM | 44.7% revenue growth vs IMVT's -21.3% |
| Quality / Margins | CRVS | 3.5% margin vs SXTC's -189.8% |
| Stability / Safety | SXTC | Beta 1.16 vs CRVS's 1.63 |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | CRVS | +355.9% vs SXTC's -99.4% |
| Efficiency (ROA) | CRL | -2.5% ROA vs IMVT's -44.1% |
SXTC vs SBFM vs CRVS vs IMVT vs CRL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
FY 2025
SXTC vs SBFM vs CRVS vs IMVT vs CRL — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCRLLAGGINGIMVT
Who Leads Where
CRL leads in 2 of 6 categories
SBFM leads 1 • CRVS leads 1 • SXTC leads 0 • IMVT leads 0 • 1 tied
Explore the data ↓IMVTImmunovant, Inc.
0leads
SXTCChina SXT Pharmaceuti…
0leads
CRVSCorvus Pharmaceutical…
1leads
SBFMSunshine Biopharma, I…
1leads
CRLCharles River Laborat…
2leads
6 Total Categories
CATEGORYLEADERvs SBFMvs CRVSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CRL4/6
Valuation MetricsMultiples, price ratios, and targets
SBFM2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CRL6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
CRVS5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CRL leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CRL and IMVT operate at a comparable scale, with $4.0B and $0 in trailing revenue. CRL is the more profitable business, keeping -4.6% of every revenue dollar as net income compared to SXTC's -189.8%. On growth, CRL holds the edge at +1.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SXTCChina SXT Pharmac… | SBFMSunshine Biopharm… | CRVSCorvus Pharmaceut… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2M | $36M | $0 | $0 | $4.0B |
| EBITDAEarnings before interest/tax | -$3M | -$6M | -$48M | -$487M | $757M |
| Net IncomeAfter-tax profit | -$3M | -$6M | -$44M | -$464M | -$185M |
| Free Cash FlowCash after capex | -$2M | -$9M | -$35M | -$423M | $391M |
| Gross MarginGross profit ÷ Revenue | +21.1% | +33.3% | — | — | +24.9% |
| Operating MarginEBIT ÷ Revenue | -154.0% | -17.9% | — | — | +11.8% |
| Net MarginNet income ÷ Revenue | -189.8% | -17.4% | — | — | -4.6% |
| FCF MarginFCF ÷ Revenue | -134.8% | -26.1% | — | — | +9.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | -7.8% | +1.2% | — | — | +1.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -119.1% | +21.5% | -15.4% | +19.7% | -160.0% |
CRL leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
SBFM leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | SXTCChina SXT Pharmac… | SBFMSunshine Biopharm… | CRVSCorvus Pharmaceut… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|---|
| Market CapShares × price | $670,507 | $757,819 | $1.2B | $5.5B | $9.0B |
| Enterprise ValueMkt cap + debt − cash | -$16M | -$8M | $1.2B | $4.8B | $11.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.20x | -0.15x | -27.53x | -9.97x | -62.52x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | 16.42x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | 12.98x |
| Price / SalesMarket cap ÷ Revenue | 0.39x | 0.02x | — | — | 2.24x |
| Price / BookPrice ÷ Book value/share | 0.04x | 0.03x | 19.01x | 5.83x | 2.81x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | 17.31x |
SBFM leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
CRL leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
CRL delivers a -5.7% return on equity — every $100 of shareholder capital generates $-6 in annual profit, vs $-47 for IMVT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CRL's 0.95x. On the Piotroski fundamental quality scale (0–9), SXTC scores 4/9 vs SBFM's 1/9, reflecting mixed financial health.
| Metric | SXTCChina SXT Pharmac… | SBFMSunshine Biopharm… | CRVSCorvus Pharmaceut… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -21.4% | -24.6% | -38.9% | -47.1% | -5.7% |
| ROA (TTM)Return on assets | -15.2% | -19.7% | -35.7% | -44.1% | -2.5% |
| ROICReturn on invested capital | -142.0% | -42.9% | -78.1% | — | +6.3% |
| ROCEReturn on capital employed | -17.9% | -25.2% | -90.2% | -66.1% | +8.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 1 | 3 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.06x | 0.04x | 0.02x | 0.00x | 0.95x |
| Net DebtTotal debt minus cash | -$17M | -$9M | -$4M | -$714M | $2.9B |
| Cash & Equiv.Liquid assets | $18M | $10M | $5M | $714M | $214M |
| Total DebtShort + long-term debt | $983,877 | $952,480 | $937,000 | $98,000 | $3.1B |
| Interest CoverageEBIT ÷ Interest expense | -4.14x | -757.53x | -18.29x | — | 6.38x |
CRL leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
CRVS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CRVS five years ago would be worth $50,137 today (with dividends reinvested), compared to $1 for SBFM. Over the past 12 months, CRVS leads with a +355.9% total return vs SXTC's -99.4%. The 3-year compound annual growth rate (CAGR) favors CRVS at 123.9% vs SBFM's -89.8% — a key indicator of consistent wealth creation.
| Metric | SXTCChina SXT Pharmac… | SBFMSunshine Biopharm… | CRVSCorvus Pharmaceut… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -99.4% | -15.6% | +99.3% | +5.1% | -10.1% |
| 1-Year ReturnPast 12 months | -99.4% | -15.0% | +355.9% | +96.1% | +32.8% |
| 3-Year ReturnCumulative with dividends | -99.8% | -99.9% | +1022.3% | +40.9% | -4.2% |
| 5-Year ReturnCumulative with dividends | -100.0% | -100.0% | +401.4% | +62.4% | -46.9% |
| 10-Year ReturnCumulative with dividends | -100.0% | -100.0% | +17.1% | +173.6% | +119.2% |
| CAGR (3Y)Annualised 3-year return | -87.6% | -89.8% | +123.9% | +12.1% | -1.4% |
CRVS leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SXTC and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
SXTC is the less volatile stock with a 1.16 beta — it tends to amplify market swings less than CRVS's 1.63 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.5% from its 52-week high vs SXTC's 0.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SXTCChina SXT Pharmac… | SBFMSunshine Biopharm… | CRVSCorvus Pharmaceut… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.16x | 1.31x | 1.63x | 1.37x | 1.52x |
| 52-Week HighHighest price in past year | $1046.98 | $2.43 | $26.95 | $30.09 | $228.88 |
| 52-Week LowLowest price in past year | $0.08 | $0.95 | $3.17 | $13.36 | $131.30 |
| % of 52W HighCurrent price vs 52-week peak | +0.2% | +44.4% | +54.1% | +90.5% | +79.5% |
| RSI (14)Momentum oscillator 0–100 | 30.7 | 56.2 | 49.2 | 60.2 | 57.2 |
| Avg Volume (50D)Average daily shares traded | 55K | 38K | 1.2M | 1.4M | 806K |
Evenly matched — SXTC and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: CRVS as "Buy", IMVT as "Buy", CRL as "Buy". Consensus price targets imply 127.3% upside for CRVS (target: $33) vs 12.9% for CRL (target: $205).
| Metric | SXTCChina SXT Pharmac… | SBFMSunshine Biopharm… | CRVSCorvus Pharmaceut… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | — | $33.17 | $45.50 | $205.43 |
| # AnalystsCovering analysts | — | — | 13 | 23 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — | 1 |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +100.0% | 0.0% | 0.0% | +4.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CRL leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SBFM leads in 1 (Valuation Metrics). 1 tied.
Best OverallCharles River Laboratories … (CRL)Leads 2 of 6 categories
Loading custom metrics...
SXTC vs SBFM vs CRVS vs IMVT vs CRL: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is SXTC or SBFM or CRVS or IMVT or CRL a better buy right now?
For growth investors, Sunshine Biopharma, Inc.
(SBFM) is the stronger pick with 44. 7% revenue growth year-over-year, versus -9. 7% for China SXT Pharmaceuticals, Inc. (SXTC). Analysts rate Corvus Pharmaceuticals, Inc. (CRVS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SXTC or SBFM or CRVS or IMVT or CRL?
Over the past 5 years, Corvus Pharmaceuticals, Inc.
(CRVS) delivered a total return of +401. 4%, compared to -100. 0% for Sunshine Biopharma, Inc. (SBFM). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus SBFM's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SXTC or SBFM or CRVS or IMVT or CRL?
By beta (market sensitivity over 5 years), China SXT Pharmaceuticals, Inc.
(SXTC) is the lower-risk stock at 1. 16β versus Corvus Pharmaceuticals, Inc. 's 1. 63β — meaning CRVS is approximately 41% more volatile than SXTC relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — SXTC or SBFM or CRVS or IMVT or CRL?
By revenue growth (latest reported year), Sunshine Biopharma, Inc.
(SBFM) is pulling ahead at 44. 7% versus -9. 7% for China SXT Pharmaceuticals, Inc. (SXTC). On earnings-per-share growth, the picture is similar: Sunshine Biopharma, Inc. grew EPS 97. 9% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, SBFM leads at 434. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SXTC or SBFM or CRVS or IMVT or CRL?
Corvus Pharmaceuticals, Inc.
(CRVS) is the more profitable company, earning 0. 0% net margin versus -189. 8% for China SXT Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRL leads at 12. 6% versus -154. 0% for SXTC. At the gross margin level — before operating expenses — SBFM leads at 30. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is SXTC or SBFM or CRVS or IMVT or CRL more undervalued right now?
Analyst consensus price targets imply the most upside for CRVS: 127.
3% to $33. 17.
07Which pays a better dividend — SXTC or SBFM or CRVS or IMVT or CRL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is SXTC or SBFM or CRVS or IMVT or CRL better for a retirement portfolio?
For long-horizon retirement investors, China SXT Pharmaceuticals, Inc.
(SXTC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 16)). Corvus Pharmaceuticals, Inc. (CRVS) carries a higher beta of 1. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SXTC: -100. 0%, CRVS: +17. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between SXTC and SBFM and CRVS and IMVT and CRL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SXTC is a small-cap quality compounder stock; SBFM is a small-cap high-growth stock; CRVS is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; CRL is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(SXTC: -7.8% · SBFM: 1.2%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.